DLBCL Landscape Shifts Dramatically With Axicabtagene Ciloleucel FDA Approval – OncLive
OncLive |
DLBCL Landscape Shifts Dramatically With Axicabtagene Ciloleucel FDA Approval
OncLive The non–Hodgkin lymphoma landscape recently underwent a major transformation, as researchers in the field saw the FDA approval of axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for … The FDA has just approved the revolutionary genetic modification treatment |
